Cheap generic versions of a groundbreaking HIV-prevention jab should be available in more than 100 countries from 2027, ...

Approved in June for people at high risk of HIV, Yeztugo was shown to be nearly 100% effective at preventing infection in large trials.

Doctors at DAP Health have begun administering a new twice-a-year injectable HIV prevention medication, which was approved by the Food and Drug Administration in June. Gilead's drug lenacapavir ...

An HIV prevention drug will be made available at a new, low cost in 120 low- and middle-income countries starting in 2027, according to an announcement yesterday. The move is being called a “once-in-a ...

The CDC is recommending a groundbreaking drug to help prevent HIV, as advocates urged CVS Health to reverse a recent decision ...

CVS Health (NYSE:CVS), one of the leading health insurers in the U.S. and owner of the Pharmacy Benefit Manager Caremark, will not add Yeztego, Gilead’s (NASDAQ:GILD) newly approved HIV PrEP, to its ...

CVS Health Inc. CVS said it will not add Gilead Sciences Inc.’s GILD new HIV prevention drug Yeztugo to its commercial plans. In June, the U.S. Food and Drug Administration (FDA) approved Gilead ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

Shares of Gilead Sciences, Inc. (GILD) tumbled 2.2% on Aug. 21, after pharmacy benefit manager CVS Health (CVS) decided not to add the former’s new HIV prevention drug, Yeztugo (lenacapavir), to its ...

(Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite ...